Literature DB >> 32569253

Evaluation of Liquid Versus Dry Specimen Transport With a Newly Validated Isothermal Amplification High-Risk Human Papillomavirus Assay.

Jingfen Sun1, Suhui Wu1, Longhua Hu1, Haixia Shang1, Yufeng Yang1, Robert Pretorius2, Yaling Huang1, Xi Yang1, Xiaoqin Wu1, Jerome Belinson.   

Abstract

OBJECTIVE: The aim of the study was to determine whether the proportion of positive high-risk human papillomavirus (HR-HPV) tests in endocervical specimens transported dry differs from paired specimens transported in liquid media.
METHODS: Five hundred women aged of 30 to 55 years were recruited, Shanxi Bethune Hospital, China. Two samples were collected from the endocervix per patient, one placed into empty vial, the other into a liquid transport solution. All samples were analyzed by AmpFire HR-HPV assay.
RESULTS: Total 1,000 samples collected from 500 patients were analyzed by the AmpFire HR-HPV assay. The total invalid rate was 0.2% (2/1,000). The proportion of endocervical samples testing positive for HR-HPV transported dry (42.2%, 210/498 [95% CI = 37.8%-46.6%]) was similar to the proportion of paired endocervical samples testing positive transported in liquid media (40.4%, 201/498 [95% CI = 36.0%-44.8%], p = .18 [McNemar test]). That the 2 transport methods are likely measuring the same positive (and negative) specimens is suggested by the finding that κ value for the correlation of positive HR-HPV in endocervical specimens transported dry with those transported in liquid media was 0.86 (95% CI = 0.81-0.90).
CONCLUSIONS: Endocervical specimens transported dry have similar proportion of positive HR-HPV tests as those transported in liquid media. Dry brush transport of endocervical samples paired with the special characteristics of AmpFire HR-HPV may become an important addition to population based cervical cancer screening.

Entities:  

Mesh:

Year:  2020        PMID: 32569253     DOI: 10.1097/LGT.0000000000000546

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  2 in total

1.  Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening.

Authors:  Wei Zhang; Hui Du; Xia Huang; Chun Wang; Xianzhi Duan; Yan Liu; Bin Shi; Wei Zhang; Xinfeng Qu; Lihui Wei; M Schiffman; J L Belinson; Ruifang Wu
Journal:  Infect Agent Cancer       Date:  2020-10-23       Impact factor: 2.965

2.  Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management.

Authors:  Kanan T Desai; Clement A Adepiti; Mark Schiffman; Didem Egemen; Julia C Gage; Nicolas Wentzensen; Silvia de Sanjose; Robert D Burk; Kayode O Ajenifuja
Journal:  Int J Cancer       Date:  2022-06-24       Impact factor: 7.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.